000041676 000__ 01518cam\a22003135i\4500
000041676 001__ 41676
000041676 003__ SzGeWIPO
000041676 005__ 20210318105239.0
000041676 008__ 200609s2018\\\\sz\\\\\\r\\\\\000\0\eng\d
000041676 020__ $$a9783845294018
000041676 0247_ $$ahttp://dx.doi.org/10.5771/9783845294018$$2doi
000041676 040__ $$aSzGeWIPO$$beng$$erda
000041676 041__ $$aeng
000041676 1001_ $$aNonaka, Hirotaka
000041676 24500 $$aFTO (Freedom to Operate) in the Pharmaceutical Industry /
000041676 250__ $$a1st ed.
000041676 264_1 $$a[Baden-Baden, Germany] :$$bNomos,$$c2018.
000041676 300__ $$a63 pages
000041676 336__ $$atext$$btxt$$2rdacontent
000041676 337__ $$aunmediated$$bn$$2rdamedia
000041676 338__ $$avolume$$bnc$$2rdacarrier
000041676 500__ $$aThis resource was extracted from the Directory of Open Access Books (DOAB)
000041676 520__ $$aFTO licensing in the pharmaceutical industry deserves special consideration because of the large economic scale of the market, expensive cost of R&D, extremely low success rate, and easy duplication of the drug. Taking these unique aspects into consideration, the author first explaines how to perform a good FTO search and conclude an appropriate FTO licensing agreement, and then points out two issues; (i) the issue of FTO licensing and EU competition, especially the unreasonable application of the Guideline, and (ii) the issue of FTO licensing and differentiating between a bio venture company and a pharmaceutical company. Solutions for these issues are proposed.
000041676 542__ $$fCC-BY-NC-ND
000041676 650__ $$aIntellectual property$$xPatent
000041676 650__ $$aEU competition law
000041676 650__ $$aPharmaceutical industry
000041676 650__ $$aLicense
000041676 85641 $$uhttps://www.doabooks.org/doab?func=search&query=rid%3A29406$$yView this Ebook
000041676 902__ $$a41676_en
000041676 903__ $$aMunich Intellectual Property Law Center - MIPLC
000041676 904__ $$aBook
000041676 980__ $$aBIB